Amgen second-quarter profit tops street.
Amgen also announced that it has a deal with GlaxoSmithKline Plc under which the British drugmaker will commercialize Amgen's eagerly-awaited experimental osteoporosis drug denosumab in Europe and emerging markets. The biotech company raised its 2009 earnings forecast to $4.80 to $4.95 per share from its prior view of $4.55 to $4.75 per share. Amgen shares closed the week up $1.39, or 2%, at $62.31.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||TOP STORIES; revenue report|
|Article Type:||Brief article|
|Date:||Aug 3, 2009|
|Previous Article:||Sanofi to buy Merck's Merial stake for $4 billion.|
|Next Article:||WellCare Health Plans Inc.|